Irritable bowel syndrome (IBS) is the most common gastrointestinal condition worldwide, affecting about 1 in 10 people, ...
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported a strong start to 2026 and reiterated its full-year outlook, pointing to ...
Abdominal pain, cramping, unpredictable trips to the bathroom – for the millions of Americans living with irritable bowel ...
A randomized controlled trial correlates 4 weeks of probiotics to positive microstructure and function changes in several ...
Ardelyx (ARDX) is rated Buy, driven by robust commercial execution of IBSRELA and XPHOZAH, and management's $1B revenue ...
Brain fog is the result of “bad connections” between the gut and the brain, said Gerard Clarke, a professor of ...
BIOTA Labs, an emerging medical food company revolutionizing medical nutrition for the management of gastrointestinal (GI) ...
Surveyed HCPs identified reduction of days on TPN as a top priority –– Improved quality of life, lower risk of infection and thrombosis viewed as key benefits of reduced TPN dependence –– Additional ...
U.S. net sales of $273 million in Q1 2026, primarily driven by improved net price and 5% EUTRx demand growth year-over-year – ...
There are several evidence-based lifestyle and diet changes you can make right now to support your gut. For example, eating ...
Patients with irritable bowel syndrome who consumed an elemental diet for 2 weeks reported significant improvement in ...
Certain medications were linked to a higher mortality risk in people with the disease. A pharmacist and gastroenterologist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results